## Harringtonine

MedChemExpress

Cat. No.:	HY-N0862		
CAS No.:	26833-85-2		
Molecular Formula:	C <sub>28</sub> H <sub>37</sub> NO <sub>9</sub>		
Molecular Weight:	531.59		
Target:	Influenza Virus		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	1 year
		-20°C	6 months

®

## SOLVENT & SOLUBILITY

Preparing Stock Solutio	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	1.8811 mL	9.4057 mL	18.8115 mL	
		5 mM	0.3762 mL	1.8811 mL	3.7623 mL	
		10 mM	0.1881 mL	0.9406 mL	1.8811 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
Solubility: ≥ 2. 2. Add each solve Solubility: ≥ 2. 3. Add each solve		Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (4.70 mM); Clear solution				
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.70 mM); Clear solution				
		vent one by one: 10% DMSO >> 90% corn oil 2.5 mg/mL (4.70 mM); Clear solution				

BIOLOGICAL ACTIVITY		
DIOLOGICAL ACTI		
Description	Harringtonine is a natural Cephalotaxus alkaloid that inhibits protein synthesis. Harringtonine has anti-chikungunya virus (CHIKV) activities with an EC <sub>50</sub> of 0.24 μM.	
In Vitro	Harringtonine inhibits the elongation phase of translation by preventing substrate binding to the acceptor site on the 60-S ribosome subunit and therefore block aminoacyl-tRNA binding and peptide bond formation <sup>[1]</sup> . Harringtonine displays potent inhibition of Chikungunya virus infection with an EC <sub>50</sub> of 0.24 μM. Harringtonine could inhibit other alphaviruses <sup>[2]</sup> . Harringtonine inhibits the growth of human myeloid leukemia cells in vitro at low concentrations. The mechanism of the	

О

Ò,,,

O

Η | N 0

HO"

он

antitumor action of harringtonine is considered to be an effect on protein synthesis and is characterized by breakdown of polysomes to monosomes <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay <sup>[2]</sup>	For harringtonine treatment studies with Sindbis virus, BHK21 cells are seeded into 96-well plates and infected with Sindbis virus at an MOI of 1 for 1 h prior to being washed twice with PBS and incubated with various concentrations of harringtonine
	<ul> <li>(0.1 μM, 1 μM, 5 μM, and 10 μM) at 37°C with 5% CO2. Cell supernatants are harvested for plaque assays at 24 h postinfection</li> <li>[2]</li> <li>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</li> </ul>

## **CUSTOMER VALIDATION**

PROTOCOL

- Nat Immunol. 2024 May 29.
- Nucleic Acids Res. 2019 Apr 8;47(6):e33.
- Cell Death Differ. 2022 Aug 22.
- Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):e2014457118.
- Biomed Pharmacother. 2024 Jun 11:176:116907.

See more customer validations on <u>www.MedChemExpress.com</u>

## REFERENCES

[1]. Fresno M, et al. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem. 1977 Jan;72(2):323-30.

[2]. Kaur P, et al. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob Agents Chemother. 2013 Jan;57(1):155-67.

[3]. Piao YF, et al. Growth inhibition of human myeloid leukemia cells in vitro by harringtonine. Gan To Kagaku Ryoho. 1990 Feb;17(2):281-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA